OBJECTIVES: Primary malignant liver tumours account for more than 1% of all paediatric malignancies, with the most common form being hepatoblastomas (HB). Such malignancies among Arab populations have rarely been addressed in the literature. Using data from Oman's sole national referral centre for childhood solid malignancies, this study aimed to present the nationwide Omani experience with HB over the past 21 years. METHODS: This retrospective study reviewed the medical records of all children with HB who were managed in the Royal Hospital, Muscat, Oman, between January 1991 and April 2012. Clinical, radiological and laboratory characteristics were examined as well as treatments and outcomes. RESULTS: During the study period, 15 patients with HB were treated. Of these, 10 have survived to date. Nine of the survivors were no longer receiving treatment and one patient still had the disease but was in a stable condition. Of the remaining five patients, three did not survive and two were lost to follow-up. The survival rate among patients who completed therapy was 91%. CONCLUSION: HB has an excellent prognosis in Oman. The main obstacle to improving outcomes among Omani patients is non-compliance with therapy.
OBJECTIVES:Primary malignant liver tumours account for more than 1% of all paediatric malignancies, with the most common form being hepatoblastomas (HB). Such malignancies among Arab populations have rarely been addressed in the literature. Using data from Oman's sole national referral centre for childhood solid malignancies, this study aimed to present the nationwide Omani experience with HB over the past 21 years. METHODS: This retrospective study reviewed the medical records of all children with HB who were managed in the Royal Hospital, Muscat, Oman, between January 1991 and April 2012. Clinical, radiological and laboratory characteristics were examined as well as treatments and outcomes. RESULTS: During the study period, 15 patients with HB were treated. Of these, 10 have survived to date. Nine of the survivors were no longer receiving treatment and one patient still had the disease but was in a stable condition. Of the remaining five patients, three did not survive and two were lost to follow-up. The survival rate among patients who completed therapy was 91%. CONCLUSION: HB has an excellent prognosis in Oman. The main obstacle to improving outcomes among Omani patients is non-compliance with therapy.
Entities:
Keywords:
Hepatic Cancer; Hepatoblastoma; Neoadjuvant Therapy; Oman
Authors: Ikram A Burney; Mansour S Al Moundhri; Azhar J Rizvi; Shyam S Ganguly; Rashid Al Abri; Rafi A Ashrafi Journal: Sultan Qaboos Univ Med J Date: 2008-03
Authors: J Brown; G Perilongo; E Shafford; J Keeling; J Pritchard; P Brock; C Dicks-Mireaux; A Phillips; A Vos; J Plaschkes Journal: Eur J Cancer Date: 2000-07 Impact factor: 9.162
Authors: Bassan J Allan; Bo Wang; James S Davis; Punam P Parikh; Eduardo A Perez; Holly L Neville; Juan E Sola Journal: J Pediatr Surg Date: 2013-10-05 Impact factor: 2.545
Authors: Maretta De Ioris; Laurence Brugieres; Arthur Zimmermann; Jean Keeling; Penelope Brock; Rudolf Maibach; Jon Pritchard; Liz Shafford; Joszef Zsiros; Piotr Czaudzerna; Giorgio Perilongo Journal: Eur J Cancer Date: 2007-12-31 Impact factor: 9.162
Authors: Ronald Gavidia; Soad L Fuentes; Roberto Vasquez; Miguel Bonilla; Marie-Chantal Ethier; Caroline Diorio; Miguela Caniza; Scott C Howard; Lillian Sung Journal: PLoS One Date: 2012-08-22 Impact factor: 3.240